98%
921
2 minutes
20
SETBP1 mutations are found in various clonal myeloid disorders. However, it is unclear whether they can initiate leukemia, because SETBP1 mutations typically appear as later events during oncogenesis. To answer this question, we generated a mouse model expressing mutated SETBP1 in hematopoietic tissue: this model showed profound alterations in the differentiation program of hematopoietic progenitors and developed a myeloid neoplasm with megakaryocytic dysplasia, splenomegaly, and bone marrow fibrosis, prompting us to investigate SETBP1 mutations in a cohort of 36 triple-negative primary myelofibrosis (TN-PMF) cases. We identified 2 distinct subgroups, one carrying SETBP1 mutations and the other completely devoid of somatic variants. Clinically, a striking difference in disease aggressiveness was noted, with patients with SETBP1 mutation showing a much worse clinical course. In contrast to myelodysplastic/myeloproliferative neoplasms, in which SETBP1 mutations are mostly found as a late clonal event, single-cell clonal hierarchy reconstruction in 3 patients with TN-PMF from our cohort revealed SETBP1 to be a very early event, suggesting that the phenotype of the different SETBP1+ disorders may be shaped by the opposite hierarchy of the same clonal SETBP1 variants.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1182/blood.2023021349 | DOI Listing |
Neurogenetics
August 2025
Speech and Language Team, Murdoch Children's Research Institute, c/o 50 Flemington Road, Parkville, VIC, 3052, Australia.
Schinzel-Giedion Syndrome (SGS) is a rare neurodevelopmental disorder caused by pathogenic SETBP1 gain-of-function variants. SGS medical features have been well described. Associated skills critical to quality of life have such as communication, feeding, and motor skills are yet to be characterised.
View Article and Find Full Text PDFCancer Sci
August 2025
Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Although mTOR signaling plays a key role in acute myeloid leukemia (AML), mTOR inhibitors have shown limited efficacy against AML in clinical trials. In this study, we found that the anti-leukemic effect of mTOR inhibition was mediated in part through the TP53 pathway. mTOR inhibition by rapamycin and TP53 activation by DS-5272 collaboratively induced the downregulation of MYC and MCL1 partly through miR-34a, thereby inducing cell cycle arrest and apoptosis in AML cells.
View Article and Find Full Text PDFCase Rep Oncol
July 2025
Center for Breast Diseases and Breast Cancer, Hokuto Hospital and Clinic, Obihiro, Japan.
Introduction: One-step nucleic acid amplification (OSNA) for the analysis of sentinel lymph nodes is now widely used as a reliable tool for the intraoperative diagnosis of breast cancer metastasis based on the quantification of CK19 mRNA. However, discrepancies have been noted between the molecular diagnosis and histological evaluation, potentially due to differences in tissue sampling or technical limitations. Furthermore, false-negative results may occur when target mRNA expression is reduced.
View Article and Find Full Text PDFInt J Mol Sci
July 2025
Cytogenetic Laboratory, Cell and Gene Therapy Program, Instituto Nacional de Câncer (INCA), Rio de Janeiro 20230-130, RJ, Brazil.
This study aimed to identify genetic variants using a customized next-generation sequencing (NGS) panel for pediatric myelodysplastic syndrome (pMDS) and to explore their associations with cytogenetic and clinical characteristics. Cytogenetic analyses were conducted using G-banding and fluorescence in situ hybridization. NGS was performed with the Ion Torrent Personal Genome Machine for the following genes: , , , , , , , , , , , , , , and .
View Article and Find Full Text PDFLeuk Res
September 2025
Department of Medicine, Hematology Division, Stanford University School of Medicine, Stanford, CA, United States; Stanford Cancer Institute, Stanford, CA, United States.
We analyzed 268 patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) to determine the impact of their molecular taxonomic features on patient's clinical outcomes and responsiveness to therapy with hypomethylating agents (HMA). They were hierarchically classified via next-generation sequencing into molecular taxonomic groups based on previously described hierarchical mutational clusters (Bernard E et al, Blood 2024). The groups varied in size, molecular complexity and patient outcomes.
View Article and Find Full Text PDF